Co-designing a behavioural intervention for reducing the impact of chemotherapy-induced peripheral neuropathy symptoms: An evidence- and theory-driven approach

Eur J Cancer Care (Engl). 2022 Nov;31(6):e13671. doi: 10.1111/ecc.13671. Epub 2022 Aug 12.

Abstract

Objective: This study aims to co-design an evidence- and theory-based behavioural intervention to reduce the impact of chemotherapy-induced peripheral neuropathy (CIPN) symptoms on patients' quality of life.

Methods: Guided by the Medical Research Council Framework for developing and evaluating complex interventions, our intervention development process was guided by (a) findings of systematic reviews, (b) inductive analysis of 39 h of observational fieldwork, 12 patient and 11 clinician interviews, (c) deductive analysis using the Common-Sense Model to develop a Self-Regulation Model of CIPN and (d) 17 patients and 18 clinicians co-designing the intervention.

Results: CIPN perception and coping behaviours were highlighted as processes to target when co-designing an intervention. The processes targeted in our intervention are CIPN perception and coping behaviours, namely, (a) self-monitoring of symptoms, (b) communicating and early reporting of symptoms to clinicians, (c) participating in making chemotherapy dose reduction decisions with their clinicians and (d) engaging in self-management and safety strategies to reduce impact of CIPN symptoms. To address these, a behavioural intervention was deemed suitable.

Conclusion: We developed a self-regulation model of CIPN and a logic model for documenting the proposed mechanism of action of our co-designed behavioural intervention for reducing impact of CIPN symptoms.

Keywords: Common Sense Model; cancer; chemotherapy; chemotherapy-induced peripheral neuropathy; experience-based co-design; intervention development.

Publication types

  • Observational Study

MeSH terms

  • Antineoplastic Agents* / adverse effects
  • Humans
  • Peripheral Nervous System Diseases* / chemically induced
  • Peripheral Nervous System Diseases* / therapy
  • Quality of Life
  • Systematic Reviews as Topic

Substances

  • Antineoplastic Agents